Novartis designs maintenance sales by 2017

Sao Paulo-the Novartis hopes to keep in 2017 the same overall performance, in terms of sales, registered last year. In 2016, the lab suffered the impact of increased competition with generics, according to report released Wednesday (25). "We''ve made great strides in the last year. In 2017, we hope to implement our strategy and keep the organization focused on mergers and acquisitions, "said pharmaceutical CEO, Joseph Jimenez, in a statement yesterday. The company had high of 6% in the volume of medicines marketed around the world in front of 2015 2016. Net revenue, however, fell 2 percent to $48.5 billion in the period. According to the pharmacist, the performance was pressed by increasing competition in the segment of generics. Sales of these medicines have dropped 4% last year node. With that, the pharmacist has recorded net income of $6.698 billion last year, down from 5% of 2015. Nevertheless, Jimenez believes that the company "has presented a solid performance in 2016". On a quarterly basis in the fourth quarter of 2016, net sales of the company retreated 2 percent in volume and revenues, on a year earlier, to $12.322 billion. Net sales in emerging growth markets-including all markets except the United States, Canada, Western Europe, Japan, Australia and New Zealand-have grown 4%. China led the positive performance with expansion of 9%, followed by Russia (+11%) and Turkey (+ 16%). The Brazil was not cited.